- MACY-PAN’s MC4000 Walk-in Chamber has been certified as a Shanghai High-Tech Achievement Transformation Project by the Shanghai Science and Technology Commission.
- The certification places the company’s core technology within China’s “National Key Supported High-Tech Fields,” granting intellectual property protections.
- The MC4000 features a patented “U-shaped” door design that allows wheelchair users and people with limited mobility to access the chamber.
- The global hyperbaric oxygen therapy market is valued at $3.98 billion in 2025 and is projected to reach $6.71 billion by 2034, growing at a 5.96% CAGR.
- MACY-PAN, operating as Shanghai Baobang Medical Equipment Co., Ltd., has manufactured hyperbaric chambers for over 17 years and exports to more than 126 countries.
Shanghai-based MACY-PAN has received official certification from the Shanghai Science and Technology Commission for its MC4000 Walk-in Chamber.
The company announced in January 2026 that its flagship hyperbaric oxygen therapy device passed the public announcement period and obtained the High-Tech Achievement Transformation Project certificate.
The recognition carries significant weight for the 17-year-old manufacturer. High-tech achievement transformation projects in China are designed to accelerate the commercialization of scientific research.
According to the Shanghai Intellectual Property Service Industry Association, qualifying products must demonstrate core technology research and development, practical value, and the ability to enhance productivity and innovation.
For MACY-PAN, the certification means its MC4000 technology is now classified within China’s “National Key Supported High-Tech Fields.” This classification provides legal protection under Chinese intellectual property law and validates the project’s technological innovation, market prospects, and potential economic benefit.
Technical Specifications of the MC4000
The MC4000 Walk-in Chamber is a vertical hyperbaric oxygen therapy device designed for accessibility. Its most notable feature is a patented “U-shaped” door design, registered under Patent No. ZL2020305049186.
This door configuration creates a larger entry point that accommodates wheelchairs and users with limited mobility.
The chamber operates at pressures of 1.3 to 1.4 ATA and can accommodate two people sitting together. Standard safety features include dual automatic pressure relief systems, internal and external pressure gauges for real-time monitoring, and three sealed zippers to prevent air leakage. The device delivers high-purity oxygen through headsets or masks.
MACY-PAN also offers an alternative “N-shaped” door design that provides wheelchair access while maintaining the spacious interior.
The Growing HBOT Market
The certification arrives at a favorable moment for hyperbaric oxygen therapy manufacturers.
According to Precedence Research, the global HBOT market is valued at $3.98 billion in 2025 and is projected to reach $6.71 billion by 2034. That represents a compound annual growth rate of 5.96%.
Several factors drive this expansion.
The World Health Organization estimates that 537 million adults aged 20 to 79 lived with diabetes in 2021, a number expected to rise to 643 million by 2030. Diabetes-related complications, particularly diabetic foot ulcers and chronic wounds, are primary use cases for hyperbaric oxygen therapy.
(Ed. note: The home care segment is projected to expand at the fastest rate among end-user categories, which aligns with MACY-PAN’s stated mission of bringing hyperbaric technology to residential settings.)
Asia Pacific represents a particularly dynamic region for market growth, with a projected CAGR of 6.5% through 2034. China’s large patient population, government healthcare reforms, and investments in hospital infrastructure contribute to this regional momentum.
Company Background
Shanghai Baobang Medical Equipment Co., Ltd., operating under the MACY-PAN brand, has manufactured hyperbaric oxygen chambers since 2007. The company holds ISO 13485 and ISO 9001 certifications, along with CE certification for European markets. According to its company profile, MACY-PAN exports to over 126 countries and serves more than 10,000 clients.
The manufacturer produces both soft-type and hard-type chambers across a range of configurations. Product lines include single-person seating and lying chambers, multi-person units, and the MC4000 walk-in model that received the recent certification. Operating pressures range from 1.0 to 2.0 ATA depending on the model.
MACY-PAN’s quality control process includes six stages of inspection: raw material inspection, assembly testing, 72-hour aging tests, system machine testing, final inspection, and packaging verification. The company offers OEM and ODM services for business customers.
Implications of the Certification
The Shanghai High-Tech Achievement Transformation Project certification provides tangible benefits beyond recognition.
According to the Science and Technology Commission of Shanghai Municipality, companies with high-tech project certifications may qualify for policy support in financing, talent acquisition, and digital transformation initiatives.
Other medical device manufacturers have pursued similar certifications. Lepu ScienTech Medical, for example, obtained certification for two high-tech achievement transformation projects in 2023 for its biodegradable occluder systems, citing the recognition as validation of its R&D investments and ability to translate research into commercial products.
For MACY-PAN, the certification represents government validation of its position in the hyperbaric industry. The company stated that the recognition reflects “strong affirmation from government authorities regarding the company’s innovation capabilities, technical expertise, and high-quality transformation of research outcomes.”
Market Context
The hyperbaric oxygen therapy device market continues to attract investment. Monoplace chambers dominated market share in 2024 due to their affordability and simpler operation. However, multiplace chambers and walk-in designs like the MC4000 are gaining traction in hospital settings and facilities serving patients with mobility challenges.
The wound healing segment accounted for the largest share of HBOT applications in 2024. Decompression sickness treatment is projected to grow at the fastest rate, driven by increased recreational diving activity and the establishment of hyperbaric facilities in coastal regions.
North America held a 31% market share in 2024, supported by accredited hyperbaric centers, favorable reimbursement policies, and the prevalence of diabetes-related wounds. European and Asia Pacific markets are expected to grow at significant rates through the forecast period.
